Norwood says transplantation tolerance trial begins

New York, Dec. 7 - Norwood Abbey Ltd. said a trial has started to determine whether tolerance to donated organ and tissue transplants can be established without the need for prolonged immuno-suppressants.

The proof of concept pre-clinical study will examine whether the thymus, having been reactivated by Norwood Immunology's technology can, in the presence of donor haemopoietic stem cells (the stem cells that form blood and immune cells), create a new immune system that is tolerant to that donor.

In particular, the trial is examining whether a transplanted kidney will be accepted as "self" and survive without the need for long-term immuno-suppressive drugs.

Norwood Immunology Ltd. is a subsidiary of Norwood Abbey, a Melbourne, Australia, medical technology company.

The trial will be conducted at Massachusetts General Hospital in Boston under a collaboration agreement signed in August. Norwood Immunology's Lupron Depot will be used in the research.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.